Revenio Group Corporation: Increased number of shares entered into trade register

Report this content

Revenio Group Corporation, Stock Exchange Release, June 5, 2020 at 9.00


Total of 20,490 new share subscriptions based on the company's 2015B stock options and total of 7,725 new share subscriptions based on the company’s 2015C stock options approved by the Board of Directors of Revenio Group Corporation on June 2, 2020, have been entered into the trade register today. The share subscription price under 2015B option rights was 9.84 EUR per share and the share subscription price under 2015C option rights was 12.78 EUR per share. The subscription period for 2015B options was May 31, 2018 – May 31, 2020. The subscription period for 2015C options is May 31, 2019 – May 31, 2021.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,627,236. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on June 8, 2020.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Jouni Toijala, CEO, tel.  +358 50 484 0085


Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media 

Revenio Group in brief

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.

The Revenio Group consists of Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.